Advertisement
Document › Details
Biognosys AG. (8/8/19). "Press Release: Biognosys Completes Series G Financing Round to Accelerate its Expansion into Clinical Trials Market". Schlieren.
Organisation | Biognosys AG | |
Group | Bruker (Group) | |
Organisation 2 | NN (NO NAME) | |
Group | OTHER | |
Product | mass spectrometry-based proteomic research test | |
Product 2 | venture capital | |
Index term | Biognosys–SEVERAL: investment, 201908 financing round Series G from existing + new institutional + private investors | |
Person | Rinner, Oliver (Biognosys 202109 CEO + Co-Founder) | |
Person 2 | Novak, Lidia (Biognosys 2019089 CFO) | |
Biognosys closes Series G round with new and existing investors to accelerate implementation of discovery proteomics in clinical trials.
Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company has raised new funds in Series G financing round.
Biognosys provides proteomics research services to innovative pharma and biotech firms. They use the company’s technology in their pre-clinical research, providing deep and precise protein expression profiling for the development of biomarkers and analysis of mode of action. As demand for the use of these services in the clinical phase is growing, the new financing round will help the company to further scale up its operations and start serving clients’ drug development projects in the clinical phases.
Dr. Oliver Rinner, Founder and CEO of Biognosys, says: “We are striving to provide the deepest and most precise proteomics data to our clients. We are very excited with the perspective to be pioneers in bringing discovery proteomics to clinical trials and provide our advanced data analysis services at a much larger scale.”
The financing round includes a new industrial investor, in addition to existing institutional and private shareholders. The funds will be invested into building a new GCP-certified facility in Switzerland, increasing current operational capacity as well as enhancing the company’s sales force, further expanding its commercial presence in the US (both East and West Coast), Europe, and Asia.
Media Contact:
Lidia Novak, CFA
Chief Financial Officer
Mobile +41 (0) 79 710 74 15
lidia.novak@biognosys.com
About Biognosys:
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com
Record changed: 2023-06-05 |
Advertisement
More documents for Bruker (Group)
- [1] NanoString Technologies, Inc.. (4/17/24). "Press Release: NanoString Technologies to Be Acquired by Bruker Corporation. Bruker Wins Competitive Auction". Seattle, WA....
- [2] Biognosys AG. (4/4/24). "Press Release: Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research". Zürich & Fremont, CA....
- [3] Bruker Corporation. (1/25/24). "Press Release: Bruker Announces Agreement to Acquire Chemspeed". Basel....
- [4] Bruker Corporation. (1/23/24). "Press Release: Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts". Zürich & Newton, MA....
- [5] Bruker Corporation. (1/3/24). "Press Release: Bruker Acquires Electron Microscopy Company Nion". Billerica, MA....
- [6] Bruker Corporation. (12/26/23). "Form 8-K. Current Report [Acquisition of Elitech Group by Bruker for €870m from PAI Partners] CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest ev...
- [7] Bruker Corporation. (10/4/23). "Press Release: Bruker Announces Majority Investment in MIRO Analytical AG, an Innovator in Compact, Highest-Precision QCL-Based Multi-Gas Analyzers (MGA)". Zürich....
- [8] Bruker Corporation. (10/3/23). "Press Release: Bruker Completes Acquisition of PhenomeX". Billerica, MA....
- [9] Bruker Corporation. (9/18/23). "Press Release: Bruker Introduces Novel 4D-Proteomics timsTOF Capabilities". Busan....
- [10] Bruker Corporation. (8/17/23). "Press Release: Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction". Billerica, MA & Emeryville, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top